Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Bret Christensen as President, Chief Executive Officer (CEO), and member of the Board of Directors at DermTech, a leader in precision dermatology enabled by a non-invasive skin genomics platform.
“Bret Christensen is a strategic and visionary leader with more than 20 years of successful experience in marketing, sales, and management roles for top genetics testing, healthcare, and medical technology companies,” said Leslie Loveless, Slone Partners CEO.
Christensen comes to DermTech after spending six years as Chief Commercial Officer at Insulet, where he oversaw sales growth from approximately $367 million to $1.1 billion. From August 2013 to May 2017, Christensen served as general manager of Preventive Care at Myriad Genetics, Inc. Previously, Christensen held several executive positions at Hologic, Inc., including vice president of sales and marketing of its Gynecologic Surgical Products division. Prior to Hologic, Christensen led key market development and sales teams at Cytyc Corporation.
Also Read: AICG Launches DataLakeHouse.io Usage Analytics for Snowflake on the Snowflake Data Cloud
“Bret Christensen is a strategic and visionary leader with more than 20 years of successful experience in marketing, sales, and management roles for top genetics testing, healthcare, and medical technology companies,” said Leslie Loveless, Slone Partners CEO. “His knowledge and commercial expertise will serve DermTech well as it pushes forward with its business plan to transform dermatology with its revolutionary technology.”
Commenting on Christensen’s appointment, Matt Posard, DermTech’s chairman said, “Bret is well positioned to lead our growing company given his significant commercial, operations, and market access experience. We are confident that Bret’s demonstrated success and expertise in the diagnostics industry align with DermTech’s strategy to fully capitalize on commercializing its genomic products and executing against its many growth opportunities. The board looks forward to working with Bret and the management team to create meaningful value for stockholders.”
SOURCE: PRWeb